Syncona Limited

Equities

BACT

GG00B8P59C08

Investment Holding Companies

Market Closed - London S.E. 12:35:07 2024-03-28 pm EDT 5-day change 1st Jan Change
123 GBX +0.16% Intraday chart for Syncona Limited -4.21% -0.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Syncona portfolio company Autolus posts widened loss for 2023 AN
Syncona’s Takeover of Freeline Therapeutics Becomes Effective MT
Freeline shareholders approve Syncona acquisition AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona MT
Syncona portfolio strengthens in third quarter thanks to Autolus AN
Syncona's Fiscal Q3 NAV Declines MT
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023. CI
Syncona notes FDA acceptance of Autolus's BLA for obe-cel AN
Syncona says Freeline trial for Gaucher disease treatment positive AN
Syncona notes Beacon's "encouraging" AGTC-501 trial data AN
Molten Ventures completes raise; Saietta proposes one AN
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
FTSE 100 Closes Down 0.17% After Autumn Statement DJ
Syncona agrees to buyout deal with Freeline Therapeutics AN
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Sector Update: Health Care MT
Syncona to Take Over Freeline Therapeutics MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million MT
Syncona reports declining asset value as investment head steps down AN
Transcript : Syncona Limited, Q2 2024 Earnings Call, Nov 16, 2023
Syncona Swings to Fiscal H1 Loss; Invest Income Falls MT
Earnings Flash (SYNC.L) SYNCONA Posts Fiscal H1 Loss GBX-8.01 MT
Syncona Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Syncona notes investee company's quarterly loss AN
Chart Syncona Limited
More charts
Syncona Limited is a Guernsey-based closed-ended investment company. The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.228 GBP
Average target price
2.453 GBP
Spread / Average Target
+99.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Syncona Limited - London S.E.
  4. News Syncona Limited
  5. Syncona to Secure 18.5% Stake in Autolus Therapeutics